BioCardia Inc. (NASDAQ:BCDA) stock is up on Friday as the company is confirming progress toward potential market approval for its CardiAMP cell therapy.
The positive movement follows the FDA’s acknowledgment that the ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) for the therapy, which targets ischemic heart failure with reduced ejection fraction (HFrEF).
Something went wrong.
FDA Update For CardiAMP Cell Therapy
The FDA’s meeting minutes indicate that BioCardia’s CardiAMP Heart Failure II Trial could pave the way for market clearance, a crucial step for the company’s growth.
